Topic: Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomized controlled trial.
Reference: The Lancet (Sep 10, 2017)
Lead by: Dr. Olga Tourin MD, FRCP, FCCP, FACP, Dipl ABIM (IM)
Duration: 45 minutes
Discussion: Evidence for management of asthma comes from closely monitored efficacy trial done in highly selected patient groups. This study was an open-label randomized trial that was closer to usual clinical practice. This study was set-up to evaluate the effectiveness and safety of initiating the once-daily inhaled combination of fluticasone furoate and vilanterol compared with continuation of maintenance therapy (usual care) in a large, real world population of patients with chronic obstructive pulmonary disease (COPD) and asthma in normal care settings. The primary endpoint was the percentage of patient who achieved asthma control based on asthma control test (ACT) scores compared to baseline.
Conclusion: In patients with a general practitioner’s diagnosis of symptomatic asthma and on maintenance inhaler therapy, initiation of a once-daily treatment regimen of combined fluticasone furoate and vilanterol improved asthma control without increasing the risk of serious adverse events when compared with optimized usual care.